Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

被引:216
作者
Llovet, JM
Mas, X
Aponte, JJ
Fuster, J
Navasa, M
Christensen, E
Rodés, J
Bruix, J
机构
[1] Univ Barcelona, IDIBAPS, Liver Unit, BCLC Grp,Hosp Clin, Barcelona 08036, Catalonia, Spain
[2] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi I Sunyer, Epidemiol Biostat Unit, Catalonia, Spain
[3] Bispebjerg Univ Hosp, Clin Internal Med, Copenhagen, Denmark
关键词
D O I
10.1136/gut.50.1.123
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Survival after liver transplantation for early hepatocellular carcinoma (HCC) is worsened by the increasing dropout rate while waiting for a donor. Aims: To assess the cost effectiveness of adjuvant therapy while waiting for liver transplantation in HCC patients. Method: Using a Markov model, a hypothetical cohort of cirrhotic patients with early HCC was considered for: (1) adjuvant treatment - resection was limited to Child-Pugh's A patients with single tumours, and percutaneous treatment was considered for Child-Pugh's A and B patients with single tumours unsuitable for resection or with up to three nodules < 3 cm; and (2) standard management. I Length of waiting time ranged from six to 24 months. Results: Surgical resection increased the transplantation rate (> 10%) and provided gains in life expectancy of 4.8-6.1 months with an acceptable cost ($40 000/ year of life gained) for waiting lists greater than or equal to 1 year whereas it was not cost effective ($74 000/life of year gained) for shorter waiting times or high dropout rate scenarios. Percutaneous treatment increased life expectancy by 5.2-6.7 months with a marginal cost of approximately $20 000/year of life gained in all cases, remaining cost effective for all waiting times. Conclusions: Adjuvant therapies for HCC while waiting for liver transplantation provide moderate gains in life expectancy and are cost effective for waiting lists of one year or more. For shorter waiting times, only percutaneous treatment confers a relevant survival advantage.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 40 条
[1]   Liver transplantation for hepatocellular carcinoma [J].
Bismuth, H ;
Majno, PE ;
Adam, R .
SEMINARS IN LIVER DISEASE, 1999, 19 (03) :311-322
[2]   Health-related quality of life after liver transplantation: A meta-analysis [J].
Bravata, DM ;
Olkin, I ;
Barnato, AE ;
Keeffe, EB ;
Owens, DK .
LIVER TRANSPLANTATION AND SURGERY, 1999, 5 (04) :318-331
[3]   Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure [J].
Bruix, J ;
Castells, A ;
Bosch, J ;
Feu, F ;
Fuster, J ;
GarciaPagan, JC ;
Visa, J ;
Bru, C ;
Rodes, J .
GASTROENTEROLOGY, 1996, 111 (04) :1018-1022
[4]   Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients [J].
Castellano, L ;
Calandra, M ;
Blanco, CD ;
deSio, I .
JOURNAL OF HEPATOLOGY, 1997, 27 (05) :862-870
[5]  
DiStasi M, 1997, SCAND J GASTROENTERO, V32, P1168
[6]   The effect of the volume of procedures at transplantation centers on mortality after liver transplantation. [J].
Edwards, EB ;
Roberts, JP ;
McBride, MA ;
Schulak, JA ;
Hunsicker, LG .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (27) :2049-2053
[7]   Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma [J].
Harnois, DM ;
Steers, J ;
Andrews, JC ;
Rubin, JC ;
Pitot, HC ;
Burgart, L ;
Wiesner, RH ;
Gores, GJ .
LIVER TRANSPLANTATION AND SURGERY, 1999, 5 (03) :192-199
[8]   Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer [J].
Hayman, JA ;
Hillner, BE ;
Harris, JR ;
Weeks, JC .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :1022-1029
[9]   Liver transplantation for malignant disease [J].
Heneghan, MA ;
O'Grady, JG .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 1999, 13 (04) :575-591
[10]  
Ishii H, 1996, CANCER, V77, P1792